NOAH - AFNET 6

Quick access

NOAH:

Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes

 

 

 

PATIENTS

Start of patient enrolment on 21st of June 2016
 

2571 patients enrolled (2502 patients randomised)
181   sites open for recruitment

Status as of 11th of July 2022

2538

Planned number of participants

 

36 randomised and treated patients pending to archieve recruitment target

 

PARTICIPATING COUNTRIES

17 european countries:

Belgium, Bulgaria, Germany, France, Greece, United Kingdom, Italy, The Netherlands, Austria, Poland, Portugal, Romania, Sweden, Spain, Czech Republic, Ukraine, Hungary

 

PUBLICATIONS

Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, deGroot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019; 0, 1–9.
doi: 10.1093/europace/euz172
 

Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Epub 2016 Feb 29.
 

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.

 

Sponsor

Atrial Fibrillation NETwork (AFNET), Münster, Germany

 

Scientific leader

International Chief Investigator:

Prof. Paulus Kirchhof, Hamburg, Germany

 

Registration

 ClinicalTrials.gov: NCT02618577

 ISRCTN 17309850

EudraCT number: 2015-003997-33